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The work of Huggins and Hodges (Huggins and Hodges, 1941)
established that androgen deprivation in patients suffering from
prostate cancer results in a favourable response in the majority.
Since such treatment is palliative in nature, it has traditionally been
reserved for those with either locally advanced or metastatic disease.
Androgen deprivation can be achieved either medically or
surgically. Surgical castration is still considered the ‘gold stan-
dard’ endocrine treatment. Medical castration can be achieved by
depot LHRH agonists such as goserelin and buserelin. Oral
synthetic oestrogens e.g. diethylstilboestrol can also bring about
castrate levels of testosterone. In addition steroidal antiandrogens
such as cyproterone may be used as monotherapy to reduce serum
testosterone and interfere with androgen activity at a cellular level.
D17DT is an immunogen consisting of the GnRH (gonado-
trophin releasing hormone) decapetide as a hapten, linked through
its amino terminus via a spacer to diphtheria toxoid. The conjugate
is formulated as a sterile, milky-white, semi-viscous, water-in-oil
injection. In experiments, injection into rabbits has been shown to
result in production of anti-GnRH antibodies. In addition, passive
immunisation via intraperitoneal injection of anti-GnRH anti-
bodies in nude mice bearing oestrogen sensitive MCF7 human
breast cancer xenografts inhibits tumour growth (Jacobs et al,
1999).
As the first study of this vaccine in man, the primary aim of this
pilot study was to establish the safety and tolerance of two doses of
D17DT, 30 and 100 mg, as an intramuscular injection and to assess
production of anti-GnRH antibodies. Secondary endpoints were
suppression of serum testosterone and PSA levels.
MATERIALS AND METHODS
Local Ethics Committee approval was granted for the study.
Twelve men with advanced prostate cancer (mean age 75 years)
who were suitable for endocrine treatment were recruited. All of
these men had locally advanced histologically-proven T3/4
prostate cancer and 1 patient was found during the course of the
study to have bony metastases. All patients had a life expectancy
of at least 3 months and WHO performance status of 2 or less at
the beginning of the study. Informed consent was obtained prior to
study commencement.
The first 6 patients recruited received the 30 mg dose and the
next six received the 100 mg dose given in three separate doses so
that patients received a total dose of either 90 or 300 mg of the
drug.
Each patient received 3 i.m. injections of D17DT, given in a
volume of 0.2 ml per injection into alternate limbs at weeks 0, 2
and 6. Patients were followed up at 2-weekly intervals for twelve
weeks and at 4 weeks thereafter. Subsequent follow-up was deter-
mined by response to treatment.
During the course of the study, blood samples were taken for
serum PSA (Abbott AxSym), LH (Abbott AxSym) and total
testosterone (RIA). Blood was centrifuged within 4 hours of being
taken and assay was performed within 24 hours.
Serum was also stored at –20°C for estimation of anti-GnRH
antibody titre. An ELISA method was used for this purpose. Serial
dilutions of sera were incubated in a 96-well plate which had been
coated with GnRH-BSA (this consisted of the specific GnRH
peptide conjugated to bovine serum albumin) antigen. Anti-GnRH
antibodies bound to the antigen were detected using goat anti-
human antibody conjugated to alkaline phosphatase. P-nitrophenyl
phosphatase was added as the substrate and the resultant colour
change assessed by absorbance at 405 nM. Titres for patient sera
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included in the assay.
During the course of the study any adverse reactions were
noted. Attention was paid specifically to the presence of injection
site reactions.
RESULTS
Overall the drug was well tolerated. Adverse events included
moderate injection site pain in 9 patients. This lasted between 1
and 11 days post-injection and was not apparent after every
injection in these patients. Two patients described mild ‘flu’-type
symptoms of shivering and headache which lasted up to 2 days on
single occasions. These may have been unrelated to the drug.
Prior to immunization all patients had undetectable GnRH anti-
body titres. Eleven of the 12 patients developed anti-GnRH anti-
bodies during the course of the study, although not all to the same
degree (Figures 3 and 6). A marked GnRH antibody titre of over
1000 U (U= arbitrary units) was seen in patients 2, 4, 5, 7 and 12.
In the remaining patients, the antibody rise was not as significant
and ranged from a maximum titre of between 0 and 400 U.
Immunization with D17DT resulted in significant reduction of
serum testosterone in 5 patients (2, 4, 5, 7 and 12). Castrate levels
were seen in patients 4, 5, 7 and 12, achieved between 56 and 98
days post injection (Figures 1 and 4). In patient 2 a partial, but
clinically significant reduction in testosterone to a minimum value
of 4.9 mmol/l was seen 112 days post injection. In all of these
patients the decline in serum testosterone seemed to coincide with
the peak antibody titre. The fall in serum testosterone was accom-
panied by fall in LH and FSH. In particular, LH was undetectable
in patients 4, 5, 7 and 12, who of course had the best testosterone
response.
Patient 11 was recruited to the trial following a TURP
(transurethral resection of prostate) which showed a poorly
differentiated adenocarcinoma. A subsequent bone scan revealed
multiple metastases. At that stage he had received two doses of
D17DT and it was felt that conventional therapy was needed. His
results are therefore not included in the figures.
Not surprisingly, PSA fell significantly in those patients whose
testosterone was suppressed during the course of the study
(Figures 2 and 5). Follow up has continued on these patients. In
patient 2, who had a partial response, serum testosterone gradually
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Figure 1 Testosterone changes post injection (30 mg group)
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Figure 3 GnRH antibody titres post injection (30 mg group)
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Figure 4 Testosterone changes postinjection (100 mg group)
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Figure 2 PSA changes post injection (30 mg group)increased back towards the normal range from 168 days post-
injection. In patients 4 and 5 (30 mg group) serum testosterone
began to rise as antibody titre gradually declined, though castrate
levels were maintained for between 8 and 9 months. Follow up
continues on the patients in the 100 mcg group who responded (7
and 12). In these patients, serum testosterone remained at castrate
levels for 9 months and has now started to return towards the
normal range.
DISCUSSION
This study shows that even a fractional dose of D17DT can elicit a
response in some patients and that antibodies raised against a
specific hormone (GnRH) can induce a sustained beneficial
response in patients with advanced prostate cancer. Previous work
in animals has shown that production of anti-GnRH antibodies in
response to immunisation causes a decline in testosterone and
testicular atrophy in rodents (Jayashankar et al, 1989). However,
experience in humans is limited (Talwar, 1997). A similar type of
vaccine has been shown to inhibit gonadotrophins in post-
menopausal women (Gual et al, 1997). This paper demonstrates
‘proof of principle’ in patients with prostate cancer. This novel
form of immunotherapy has been described recently in a patient
with refractory hypercalcaemia from metastatic parathyroid carci-
noma (Bradwell and Harvey, 1999). The patient was immunised
against her own parathyroid hormone, with a resultant fall in
serum calcium and clinical improvement.
The production of antibodies to GnRH is a complex process
(Stevenson, 1999) and depends on successful antigen uptake and
presentation to T and B lymphocytes. Immunization with D17DT
will result in the production of antibodies both to DT and to GnRH.
In this study the anti-GnRH antibody titre was measured specifi-
cally by ELISA. A previous paper has shown that passive immuni-
sation of female nude mice with affinity purified anti-GnRH
antibodies produced from the serum of rabbits immunised with
D17DT resulted in atrophy of reproductive organs (Jacobs et al,
1999). The authors showed that passive immunisation with anti-
GnRH antibodies resulted in a significant fall in serum LH and
oestrogen compared with controls. This provides evidence for
suppression of pituitary gonadal function by anti-GnRH antibodies.
In addition growth of the oestrogen sensitive MCF7 breast 
cancer xenograft in these mice was inhibited by administration of -
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Figure 8 LH values post injection (100 mg group)anti-GnRH antibodies. The amount of GnRH in D17DT is
extremely small and data from early work with LHRH agonists
(Walker et al, 1984) indicate that this dose would be very unlikely
to produce testosterone suppression to castrate levels. LH levels
were seen to increase slightly during the first few weeks of treat-
ment in some of the patients (Figures 7 and 8). Interestingly
however a rise was not seen in 3 of the 4 patients who developed
castrate levels of testosterone (in patient 7 there was a very slight
increase in serum LH from 7 to 8 mIU/ml) and this too would
support the fact that the GnRH effect in producing a castrate state is
negligible.
It seems from this study that the clinical response is related
quantitatively to antibody production. The patients with the
highest anti-GnRH antibody titres had the best response in terms
of testosterone and PSA suppression. Work in animals has shown
that the antibody response is dependent on many factors including
dose of drug, number of injections and the choice of adjuvant and
carrier (Ferro and Stimson, 1996). Epitope suppression is believed
to occur when a host is exposed to an immunogenic dose of carrier
protein, followed by immunization with a hapten conjugated to the
same or similar carrier molecules. The anti-hapten antibody
response is thereby suppressed and ineffectual immunisation may
occur. Since immunization against diphtheria was introduced into
the UK in 1940, most of the patients in this study will have been
exposed to the carrier protein prior to the commencement of this
trial. This may partly explain why all patients did not respond to
the same degree. However, it has been shown that the effects of
epitope suppression can be overcome by increasing the number of
doses in the immunisation regimen (Ferro and Stimson, 1996). In
addition it has been suggested that carrier pre-sensitisation (i.e.
pre-immunisation with diphtheria toxoid) may have the advantage
of adjuvant free administration. Since adjuvants have the potential
for causing a degree of tissue damage this would be desirable. This
form of immunotherapy may also be applicable to other hormone
sensitive forms of cancer, such as carcinoma of the breast.
Both 30 and 100 mg can be regarded as low doses, mainly
intended to assess tolerance rather than determine efficacy. In
terms of therapeutic efficacy, there did not appear to be a great deal
of difference between the 30 and 100 mcg dose. Both doses
produce castrate levels of testosterone lasting up to 9 months.
D17DT may have advantages over more conventional forms of
hormonal treatment in terms of ease of administration, theoretical
lack of hormonal flare and length of testosterone suppression. In
order to investigate the precise effect of D17DT on hormonal flare
it will be necessary to observe LH and testosterone levels more
closely during the initial 2 weeks of treatment. One potential
disadvantage of this treatment is the fact that it can take up to 3
months for castrate levels of testosterone to develop. The role of
hormonal therapy however in prostate cancer is set to increase.
Traditionally hormonal therapy has been delayed until the onset of
significant clinical symptoms and the decision to treat has been
based on a balance between therapeutic advantages and side-
effects from hormonal therapy. Recent studies have suggested
some degree of advantage for early androgen withdrawal when
compared to deferred therapy (Kirk et al, 1996) and many patients
who will be started on hormonal therapy in the future will in fact
be asymptomatic.
Intermittent endocrine therapy (Akakura et al, 1993) has been
proposed as a form of treatment that may be equal to continuous
treatment, and yet may give an enhanced quality of life for patients.
This form of therapy may produce a favourable biological tumour
effect (Bruchovsky et al, 1990) in that the cyclic nature of this
treatment could theoretically prolong the androgen dependent state
of a population of cancer cells. It appears that immunotherapy with
D17DT is reversible and therefore D17DT could achieve the
benefit of cyclic treatment. Further studies will need to investigate
the effect of ‘booster doses’ on testosterone suppression.
High affinity GnRH receptors are found in a high proportion of
prostate cancers (Halmos et al, 2000). The role of these receptors
in malignancy is not fully understood, although there is evidence
suggesting that blocking these receptors in nude mice bearing
androgen insensitive prostate cancer xenografts may lead to an
inhibition of tumour growth (Jungwirth et al, 1997). D17DT works
mainly around the hypothalamic-pituitary axis. It is possible
however that anti-GnRH antibodies may also have a direct effect
on prostate tumour by affecting GnRH binding to receptors.
In conclusion we have shown that the induction of antibodies to
GnRH can produce lasting, castrate levels of testosterone in men
with prostate cancer. Future studies will need to address factors in
order to assess whether this novel form of therapy can produce
reliable and predictable castration in the majority of patients.
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